

Index

A

- Acral lentiginous melanoma, 221
- Acupuncture
 - clinical studies, 443–444
 - forms and techniques, 443
 - safety, 444
- Acute lymphoblastic leukemia (ALL)
 - cardiotoxicity, 190–191
 - secondary malignancies, 192
- Acute myeloid leukemia (AML)
 - hypothyroidism, 196
 - quality of life, 195
 - secondary malignancies, 192
- Adrenal dysfunction, 354–355
- Adult survivorship, pediatric cancers
 - cancer types, 43
 - cognitive deficits, 42
 - disease surveillance, 43–44, 50–51
 - evidence-based guidelines, 42
 - incidence, 42
 - psychosocial functioning, 54
 - treatment-related late effects
 - chemotherapy, 46–48
 - neurosurgery, 44–45
 - orthopedic surgery, 45
 - radiation, 49, 51
 - risk-based surveillance, 51–52
 - second primary cancer
 - prevention, 52–53
 - thoracic and abdominal surgery, 45
- Ahmed, S.U., 71–87
- Alousi, A., 167–184
- Alternative medicine, 434
- American Cancer Society (ACS)
 - guideline, 288, 289, 294
- American Institute of Cancer Research/World Cancer Research Fund (AICR/WCRF), 288, 291, 292
- American Society of Clinical Oncology, 289
- Americans with Disabilities Act (ADA), 397, 416–417
- Andersen, B.L., 441
- Androgen deprivation therapy
 - prostate cancer, 345
 - PSA levels, 103
- Anthracyclines
 - cardiovascular system, 189–191
 - contractile dysfunction
 - angiotensin-converting enzyme inhibitors, 329
 - beta-adrenergic blockers, 329
 - cardiac myocytes loss, 327
 - ejection fraction, 329
 - patients characteristics, 328
 - treatment-related cardiac dysfunction, 327, 328
 - lymphoma, 205
- Antidepressants, 371
- Anxiety, 181–182
- Aoki, E., 187–197
- Areflexic bladder, 392
- Armodafinil, 370–371
- Aromatase inhibitors (AI), 345–346, 405–406
- Aspirin, 86
- Ater, J.L., 41–54

B

- Ballas, L., 201–214
- Bexarotene, 350

- Biliary tract obstruction, 380
- Biological therapy, melanoma
 adjuvant treatment, 230–231
 systemic treatment, 231–232
- Bleomycin, 206
- Bodurka, D.C., 125–138
- Body mass index (BMI), 289–290
- Boland, G.M., 219–235
- Bone mineral density (BMD), 344, 346
- Bortezomib, 206–207
- Botulinum toxin, 393
- Boykoff, N., 61
- Breast cancer
 aromatase inhibitors, 63, 345
 bone health, 69
 calcium and vitamin D
 supplementation, 293
 chemotherapy
 cardiac toxicity, 60–61
 neurologic toxicity, 61
 ovarian failure, 61
 second malignancies, 62
 history and physical examination, 59
 invasive breast cancer, 67
 magnetic resonance imaging, 60
 mammography, 59
 monitoring interval, 58
 noninvasive breast cancer, 68
 psychosocial functioning, 64
 radiation therapy
 cardiovascular toxicity, 62
 second malignancies, 62–63
 second primary cancer preventions, 60
 soyfoods, 294
 tamoxifen, 63
 type of monitoring, 58
 ultrasound, 59
 vertebral insufficiency fractures, 345
- Brief Fatigue Inventory, 363
- Bronchogenic carcinoma, 380
- B-type natriuretic peptide, 191
- Bupropion, 371
- Bupropion-SR (sustained release), 265–266
- C**
- Cancer prevention, 3
- Cancer-related fatigue (CRF)
 ATP dysfunction, 363
 circadian rhythm disruption, 363
 clinical evaluation, 363–365
 cytokine dysregulation, 363
 definition, 362
 diagnostic criteria, 362
- factors affecting, 364
- hypothalamic-pituitary-adrenal
 axis disturbance, 363
- neuroactive agents, peripheral release, 363
- nonpharmacologic treatment interventions
 activity enhancement, 367
 complementary therapies, 368
 dietary management, 368
 psychosocial interventions, 367
 sleep management, 368
- pharmacologic treatment interventions
 antidepressants, 371
 donepezil, 371
 multivitamins, 371
 steroids, 371
 stimulants, 369–371
 prevalence, 362
 scoring system, 363
 serotonin dysregulation, 362
- Cardiac troponins, 191
- Cardiovascular issues
 burdens and stresses, 332
 chemotherapy
 contractile dysfunction, 327–329
 myocardial dysfunction, 330–331
 cor pulmonale, 333
 endocrine disorders, 333
 external toxic exposure, 332
 interventions, 333
 pregnancies, 333
 radiation, 331–332
- Central nervous system, 49
- Cervical cancer
 second primary cancer, 130
 surveillance, 127, 141
- Champlin, C., 167–184
- Chemoradiation, 75
- Chemotherapy
 breast cancer survivors
 cardiac toxicity, 60–61
 neurologic toxicity, 61
 ovarian failure, 61
 second malignancies, 62
 cardiovascular issues
 contractile dysfunction, 327–329
 myocardial dysfunction, 330–331
 colorectal cancer survivors, 74
 head and neck cancer, 146–147
 hypogonadism, 346
 leukemia
 bone metabolism, 196
 cardiotoxicity, 190
 reproductive changes, 193–194
 secondary malignancies, 192

- lymphoma
 - cardiac adverse effects, 205
 - chemobrain, 205
 - chronic neuropathy, 206–207
 - immunodeficiency, 207
 - kidney damage, 206
 - liver enzyme abnormality, 206
 - myelodysplasia, 207
 - pulmonary adverse effects, 206
- second primary cancers, 305–306
- treatment-related late effects,
 - adult survivors
 - gonads, 48
 - heart, 46–47
 - kidneys, 48
 - liver, 47
 - lungs, 48
- Chronic lymphocytic leukemia (CLL)
 - immune function, 196
 - quality of life, 195
 - secondary malignancies, 193
- Chronic myeloid leukemia (CML)
 - bone metabolism, 196
 - cardiotoxic effects, 191
 - endocrine system, 196
 - neurologic changes, 195–196
 - quality of life, 194–195
 - secondary malignancies, 192
- Chronic obstructive pulmonary disease, 258
- Cinciripini, P.M., 264
- Circadian rhythm disruption, 363
- Clinical care delivery, 2
- Cognitive dysfunction
 - chemobrain/chemo fog, 336
 - cognitive and behavioral
 - intervention strategy, 340
 - cognitive testing, 337
 - etiology, 338–339
 - evidence-based practices, 340
 - neuropsychological assessment, 337
 - patient and family education, 340
 - patterns, 337–338
 - potential causes, 336
 - stimulant therapies, 340
 - symptoms, 340
- Cognitive impairment, 181
- Colorectal cancer, 90–93
 - metastatic disease, 79
 - noninterventional risk evaluation, 72–73
 - nonmetastatic disease
 - coloprint analyzes, 76
 - OncoDefender-CRC, 79
 - oncotype DX, 76
 - patient reactions, 73
 - physician support, 86
 - pregnancy, 83–84
 - prevention
 - alcohol and tobacco, 85–86
 - aspirin, 86
 - diet, 84–85
 - exercise activity, 85
 - hormone replacement therapy, 86
 - quality of life management
 - chemotherapy-related issues, 81–82
 - long-term radiation effects, 82–83
 - pain management, 83
 - palliation, 83
 - rectal surgery effects, 80
 - short-term radiation effects, 82
 - stomata, 79–80
 - surveillance, 75–78
 - survival rates and staging, 73–74
 - survivorship care components, 72
 - treatment modalities
 - chemoradiation, 75
 - chemotherapy, 74
 - radiation, 75
 - surgery, 74
- Community care integration, 28
 - colorectal cancer, 34
 - communication skills, 32–33
 - coordination care, 30–32
 - disparities, 33
 - health status and risk factors, 34
 - physicians and health
 - professionals, role of
 - long-term follow-up care, 29
 - multiple model, 29
 - risk assessment and risk reduction, 30
 - smoking rates, 34
- Complementary and integrative medicine (CIM)
 - categories, 435
 - evidence-based approach
 - acupuncture, 443–444
 - massage, 444–445
 - mind-body practices, 445–446
 - integrative care plans, 440, 441
 - patient-clinician communication, 436–437
 - physical well-being, 442
 - prevalence, 435–436
 - psychosocial well-being, 440–441
 - safety concerns
 - cancer promotion, 439
 - hematologic toxicity, 439
 - hepatic and renal toxicity, 438–439
 - lack of quality control standards, 439
 - metabolic interactions, 438
 - treatment interactions, 438

Complementary medicine, 434
 Computed tomography (CT), 203, 224
 Contractile dysfunction
 angiotensin-converting enzyme inhibitors, 329
 beta-adrenergic blockers, 329
 cardiac myocytes loss, 327
 ejection fraction, 329
 patients characteristics, 328
 treatment-related cardiac dysfunction, 327, 328
 Courneya, K.S., 386
 Crew, K.D., 444
 Cystectomy
 female sexual dysfunction, 408
 male sexual dysfunction, 407–408
 Cytokine dysregulation, 363
 Cytokine therapy, 351

D

Dasatinib
 CML, 191, 192
 Philadelphia chromosome–positive ALL, 191
 Davis, J.W., 95–112
 Denosumab, 347
 Depression, 181–182
 Dexrazoxane, 190
 Dextroamphetamine, 370
 Diet, 84–85
 Dietary Supplement Health and Education Act, 436
 Dietz, J.H., 386
 Donepezil, 371
 Dopamine
 bupropion, 265
 neuroadaptive effects, 260
 reward pathway, 259–260
 varenicline, 266
 Doxorubicin, 205
 Dysphagia, 152–153

E

Empathy, 422, 423
 Employment issues, 416–417
 Endocrine disorders
 adrenal dysfunction, 354–355
 antineoplastic therapy, 344
 bone metabolism disorders (*see* Osteoporosis)
 gonadal system disorders, 355–356
 hypothalamic-pituitary dysfunction

 central and nephrogenic diabetes insipidus, 354
 hyperprolactinemia, 354
 hypopituitarism, 352–353
 radiotherapy, 352
 syndrome of inappropriate antidiuretic hormone secretion, 354
 metabolic disorders
 glucose metabolism, 348–349
 hypercholesterolemia, 350
 hypertriglyceridemia, 349–350
 thyroid neoplasia and dysfunction
 hyperthyroidism, 351
 hypothyroidism, 351–352
 ionizing radiation, 350
 Endometrial cancer
 second primary cancer, 128–129
 surveillance, 126–127, 140
 Eng, C., 71–87
 Erectile dysfunction, 103–104
 Erection pain, 403
 Extragonadal germ cell tumors, 110

F

Fallopian tube/primary peritoneal cancers, 130–131
 Farber, S., 439
 Fatigue, 182
 Fever, 376
 Field cancerization process, 300
 Filipovich, A.H., 180
 Flahert, K.T., 232
 Flores, S.L., 241–249
 Foxhall, L.E., 27–35, 287–297, 299–308, 325–341, 343–356, 361–372, 375–383, 385–398, 401–411, 415–419, 421–430, 433–447
 Friedenreich, C.M., 386

G

Genitourinary (GU) cancer
 extragonadal germ cell tumors, 110
 penile cancer
 monitoring and management, 106–107
 surveillance and care eligibility, 106
 prostate cancer
 erectile dysfunction, 103–104
 hormonal therapy, 105
 lower urinary tract symptoms, 104
 postsurgical incontinence, 104
 rectal symptoms, 104
 surveillance and care eligibility, 103

- psychosocial functioning, 111–112
 - renal cell carcinoma
 - incidence, 97
 - monitoring and management, 99
 - surveillance and care eligibility, 97–99
 - risk reduction and early detection, 111
 - testicular cancer
 - hypogonadism, 108
 - infertility, 108–109
 - marrow failure/secondary malignancies, 110
 - metabolic syndrome
 - and cardiovascular disease, 109
 - neurotoxicity, 109
 - renal insufficiency, 109
 - surveillance and care eligibility, 107–108
 - urothelial cancer
 - monitoring
 - and management, 100–101
 - surveillance and care eligibility, 99–100
 - upper tract, 101–102
 - Gershenwald, J.E., 219–235
 - Gonadal system disorders, 355–356
 - Gonzales, D., 264
 - Graft-versus-host disease (GVHD), 377, 405
 - Growth hormone (GH) deficiency, 353
 - Gynecologic cancer
 - bone health, 143
 - caregivers, 137–138
 - late treatment effects
 - bone health, 135
 - chemotherapy, 134
 - hormonal therapy, 134–135
 - radiation treatment, 132–134
 - surgery, 131–132
 - psychosocial issues, 135–137
 - second primary cancer
 - cervical/vaginal/vulvar cancers, 130
 - endometrial cancer, 128–129
 - ovarian/fallopian tube/primary peritoneal cancers, 130–131
 - surveillance
 - cervical/vaginal/vulvar cancers, 127, 141
 - endometrial cancer, 126–127, 140
 - ovarian/fallopian tube/primary peritoneal cancers, 127, 142
- H**
- Habra, M.A., 241–249
 - Head and neck cancer (HNC)
 - chemotherapy, 146–147
 - hypopharynx/larynx, 149
 - nasopharynx cancer, 149, 163
 - oral cavity, 148
 - oral cavity cancer, 161
 - oropharynx cancer, 148–149, 162
 - posttreatment surveillance, 149–150
 - radiation therapy, 147
 - risk factor, 148
 - salivary cancer, 165
 - surgery, 147
 - upper aerodigestive tract function
 - dysphagia, 152–153
 - laryngeal dysfunction, 153–154
 - lymphedema, 156–157
 - normal function, 150–151
 - oral complications, 154–156
 - ototoxicity, 157
 - systemic and psychosocial effects, 158
 - Hematologic toxicity, 439
 - Hematopoietic stem cell transplantation
 - cardiovascular late effects, 175–177
 - endocrine late effects, 172–173
 - graft-versus-host disease, 178–181
 - late infections, 177–178
 - neurologic and psychosocial late effects
 - cognitive impairment, 181
 - depression and anxiety, 181–182
 - fatigue, 182
 - sexuality and sexual functioning, 182–183
 - social functioning, 183–184
 - ocular late effects, 170–171
 - oral late effects, 171
 - pulmonary late effects, 174–175
 - renal late effects, 177
 - secondary malignancy, 169–170
 - skeletal late effects, 173–174
 - Hepatitis B virus, 206
 - Heterocyclic amines (HCAs), 291
 - Hodgkin lymphoma, 305
 - cardiovascular disease, 209
 - CT technology, 203–204
 - long-term survivors, 211
 - Hoffman, K.E., 95–112
 - Hope, L., 428
 - Hormonal therapy
 - breast cancer survivors, 63
 - colorectal cancer survivors, 86
 - Host defense
 - immunologic, 376
 - nonimmunologic, 376
 - Houlston, R.S., 73

- Howlader, N., 9
 Hughes, J.R., 264
 Human papillomavirus (HPV), 304
 Humoral immunity, 377
 Hurricane Voices Breast Cancer Foundation, 336
 Hutcheson, K.A., 145–158
 Hypercholesterolemia, 350
 Hyperprolactinemia, 354
 Hyperreflexic bladder, 391
 Hypertension, 99
 Hyperthyroidism, 351
 Hypertriglyceridemia, 349–350
 Hypogammaglobulinemia, 377
 Hypogonadism, 108
 Hypoparathyroidism, 243
 Hypopharynx, 149
 Hypopituitarism, 352–353
 Hypothalamic-pituitary-adrenal axis disturbance, 363
 Hypothalamic-pituitary dysfunction
 central and nephrogenic diabetes insipidus, 354
 hyperprolactinemia, 354
 hypopituitarism, 352–353
 radiotherapy, 352
 syndrome of inappropriate antidiuretic hormone secretion, 354
 Hypothyroidism, 196, 351–352
- I**
 Imatinib. *See* Leukemia
 Immunologic deficits
 Immunologic host defense, 376
 Immunotherapy, melanoma
 adjuvant treatment, 230–231
 systemic treatment, 231–232
 Infections
 antimicrobial agents, 382–383
 impaired cellular immunity, 376–377
 impaired humoral immunity, 377
 neutropenia
 fever, 376
 hematologic malignancies, 377
 myeloablative hematopoietic stem cell transplantation, 377–379
 predisposing factors, 376
 solid tumors
 anatomic barriers, 380
 diagnosis and treatment, 381–382
 location and size, 381
 mucosal damage, 380
 obstruction, 380
 risk factors, 379–380
 urinary catheters, 380
 vascular access catheters, 380
 Infertility, 108–109
 Insurance issues, 416
 Integrative medicine center model, 440, 441
 Intrathecal baclofen pump, 393–394
 Invasive breast cancer, 67
 Ischemic heart disease, 258
- J**
 Johns, L.E., 73
 Jorenby, D.E., 264
- K**
 Kane, Jeff, 428
 Karam-Hage, M., 264
 Kegel exercise, 410
 Kim, J., 95–112
 Kroenke, C.H., 279
 Kroon, B.B., 223
 Kuban, D.A., 95–112
- L**
 Laryngeal dysfunction, 153–154
 Larynx, 149
 Lawenda, B.D., 438
 Legal issues
 advance care planning
 communication, 418
 financial and estate plans, 417
 forms, 418
 employment, 416–417
 genetic testing, 419
 insurance, 416
 intellectual property, 419
 research study participation, 419
 resources, 419
 travel and leisure, 417
 Lentigo maligna melanoma, 221
 Leukemia
 bone metabolism, 196
 cardiovascular system
 anthracyclines, 189–191
 tyrosine kinase inhibitors, 191
 endocrine system, 196
 history, 188
 immune function, 196–197
 MD Anderson symptom inventory, 195
 monoclonal antibody, 188–189
 neurologic changes, 195–196

- quality of life, 194–195
 - reproductive changes, 193–194
 - secondary malignancies
 - chemotherapy and radiation therapy, 192
 - CLL, 193
 - CML, 192
 - small-molecule inhibitor, 188–189
 - Lewis, C.M., 145–158
 - Livestrong program, 280–281
 - Lung cancer, 258
 - Lymphedema, 156–157
 - Lymphoma
 - chemotherapy
 - cardiac adverse effects, 205
 - chemobrain, 205
 - chronic neuropathy, 206–207
 - immunodeficiency, 207
 - kidney damage, 206
 - liver enzyme abnormality, 206
 - myelodysplasia, 207
 - pulmonary adverse effects, 206
 - laparotomy, 203
 - long-term survivors
 - monitoring, 211–212
 - nutrition, 213
 - passport plan, health, 213
 - physical examination, 211
 - psychosocial health and functioning, 212
 - MOPP regimen, 203
 - radiation therapy
 - breast cancer, 210
 - cardiovascular disease, 209
 - leukemia, 209–210
 - lung cancer, 210–211
 - solid tumors, 210
 - sterility, 208
 - thyroid disorders, 208
 - xerostomia, 207–208
 - splenectomy, 203–204
 - treatment options, 203–204
- M**
- Madersbacher, S., 100
 - Massage, 444–445
 - Melanoma
 - classification, 221
 - clinical history, 224
 - cost-effectiveness analysis, 224–225
 - definition, 221–222
 - epidemiology, 220
 - health care costs, 234
 - immunotherapy and biological therapy
 - adjuvant treatment, 230–231
 - systemic treatment, 231–232
 - long-term survivors
 - psychological adjustment, 233–234
 - reproductive issues, 234
 - magnetic resonance imaging, 224
 - MD Anderson mission, 222
 - primary and recurrent melanoma, 223
 - radiation therapy, 230
 - risk-reduction strategy and prevention, 225–226
 - second primary tumor, 223–224
 - single-agent chemotherapy, 233
 - surgical management
 - hyperthermic isolated limb infusion, 227
 - in-transit metastases, 227
 - late effects, 228
 - lymphedema, 227–229
 - sentinel lymph node biopsy, 226–227
 - survival rates, 222–223
 - targeted therapy, 232–233
 - Metabolic disorders
 - glucose, 348–349
 - lipid
 - hypercholesterolemia, 350
 - hypertriglyceridemia, 349–350
 - Metabolic syndrome, 109
 - Metastatic disease, 79
 - Methylphenidate, 369–370
 - Mind-body practices, 445–446
 - Mitotane, 355
 - Modafinil, 370
 - Moderate-intensity activity, 280
 - Modified Ashworth Scale, 393
 - Morrow, P.K., 57–64
 - Mosher, C.E., 279
 - Mullan, F., 11
 - Multivitamins, 371
 - Muntener, M., 102
 - Musculoskeletal pain, 387–388
 - Myocardial dysfunction
 - chemotherapy/biological agents, 330–331
 - type II agents, 330
- N**
- Nasopharynx, 149
 - National Cancer Institute, 288–289
 - National Comprehensive Cancer Network, 363
 - Neumann, C., 167–184
 - Neurogenic bowel, 391–392

- Neuropathic pain, 388–389
 Neurosurgery, 44–45
 Neurotoxicity, 109
 Neutropenia, 376
 Newell, S.A., 446
 Nichols, H.B., 279
 Nicotine dependence
 - behavioral therapy, 268–269
 - biological pathway
 - diagnosis, 261
 - neuronal adaptation, 260
 - reward pathway, 259–260
 - pharmacologic therapy
 - bupropion-SR, 265–266
 - chronic relapsing disorder, 261–262
 - components, 262
 - evidence-based guidelines, 262–263
 - nicotine replacement therapy, 262, 264–265
 - varenicline, 266–268
- Nicotine replacement therapy (NRT), 262, 264–265
- Nieweg, O.E., 223
- Nilotinib, 191
- N-nitroso compound (NOC), 291
- Nodular melanoma, 221
- Non-Hodgkin lymphoma, 202
- Nonimmunologic host defense, 376
- Noninvasive breast cancer, 68
- Nonmetastatic disease
 - coloprint analyzes, 76
 - OncoDefender-CRC, 79
 - oncotype DX, 76
- Nutrition
 - American Cancer Society guideline, 288, 289, 294
 - AICR/WCRF, 288, 291, 292
 - alcoholic beverages, 292
 - American Cancer Society, 280
 - American Society of Clinical Oncology, 289
 - calcium and vitamin D
 - supplementation, 293
 - food attitudes and behaviors, 295
 - future aspects, 295
 - meats, 291–292
 - National Cancer Institute, 288–289
 - organic foods, 292
 - phytochemicals, color, 294
 - plant-based diet, 290–291
 - self-monitoring, 282
 - sodium, 292
 - soyfoods, 294
 - vegetarian diets, 293
 - weight management, 289–290, 296
- O**
- Obesity
 - behavioral changes
 - environmental changes, 283
 - goal setting, 282
 - self-monitoring, 282–283
 - social support, 283
 - outcomes, 278–279
 - quality of life, 279
- Office of Cancer Survivorship (OCS), 10
- Oral cavity, 148
- Oral complications, 154–156
- Oropharynx, 148–149
- Orthopedic surgery, 45
- Osai, W.E., 95–112
- Osteomalacia, 348
- Osteoporosis
 - anabolic therapy, 347
 - bisphosphonate therapy, 347
 - bone mineral density, 344, 346
 - denosumab, 347
 - gonadal function, therapy
 - antiandrogen therapy, 345
 - aromatase inhibitors, 345–346
 - bilateral orchiectomy, 346
 - chemotherapy, 346
 - estrogen-and androgen-deprivation therapy, 345
 - estrogen receptor modulators, 345
 - GnRH agonist, 345, 346
 - RANKL, 345
 - vertebral insufficiency fractures, 345
 - hematopoietic stem cell
 - transplantation, 347
 - high-dose corticosteroids, 347
 - osteomalacia, 348
 - radiotherapy, 347
 - rickets, 348
 - vitamin D, 347, 348
- Ototoxicity, 157
- Ovarian cancer, 130–131
- P**
- Palliation, 83
- Palliative rehabilitation, 386
- Patch therapy, 262, 264–265
- Patient–health care provider communication

- clinic visits, 422
 - difficult news delivering
 - invitation, 426
 - knowledge, 426
 - patients final summarize, 426
 - perception, 425–426
 - proper setting creation, 425
 - empathic opportunities, 422, 423
 - exploratory statements
 - and questions, 426–429
 - patients cry
 - emotional expression, 423
 - empathy, 424
 - respectful and supportive statements, 424–425
 - Patient Protection and Affordable Care Act, 416
 - Patterson, M.L., 95–112
 - Peau d'orange, 394–395
 - Pediatric cancers. *See* Adult survivorship, pediatric cancers
 - Penile cancer, 119
 - monitoring and management, 106–107
 - surveillance and care eligibility, 106
 - Phenol, 393
 - Physiatry, 386
 - Physical inactivity
 - American Cancer Society, 280
 - behavioral changes
 - environmental changes, 283
 - goal setting, 282
 - self-monitoring, 282–283
 - social support, 283
 - comorbidity, 278
 - outcomes, 276–277
 - quality of life, 277–278
 - weight loss, 281
 - YMCA program, 280–281
 - Phytoestrogens, 439
 - Pollak, K.I., 424
 - Polycyclic aromatic hydrocarbons (PAHs), 291
 - Ponatinib, 191
 - Postvoid bladder, 392
 - Preventive rehabilitation, 386
 - Prostate cancer, 117–118
 - androgen deprivation therapy, 345
 - antiandrogen therapy, 345
 - erectile dysfunction, 103–104
 - hormonal therapy, 105
 - lower urinary tract symptoms, 104
 - osteoporotic fractures, 345
 - postsurgical incontinence, 104
 - rectal symptoms, 104
 - surveillance and care eligibility, 103
- Q**
- Quality of life (QOL)
 - AML, 195
 - CLL, 195
 - CML, 194–195
 - colorectal cancer
 - chemotherapy-related issues, 81–82
 - long-term radiation effects, 82–83
 - pain management, 83
 - palliation, 83
 - rectal surgery effects, 80
 - short-term radiation effects, 82
 - stomata, 79–80
 - obesity, 279
 - physical inactivity, 277–278
 - tyrosine kinase inhibitors, 194–195
- R**
- Radiation therapy
 - breast cancer survivors
 - cardiovascular toxicity, 62
 - second malignancies, 62–63
 - cardiovascular issues, 331–332
 - colorectal cancer survivors, 75
 - head and neck cancer, 147
 - leukemia, 192
 - lymphoma
 - breast cancer, 210
 - cardiovascular disease, 209
 - leukemia, 209–210
 - lung cancer, 210–211
 - solid tumors, 210
 - sterility, 208
 - thyroid disorders, 208
 - xerostomia, 207–208
 - melanoma, 230
 - treatment-related late effects,
 - adult survivors
 - abdomen/pelvis, 51
 - central nervous system, 49
 - head and neck, 49
 - musculoskeletal, 49
 - Radioactive iodine (RAI) therapy, thyroid cancer
 - gonadal effects, 245–246
 - oral and ocular complication, 244–245
 - secondary malignancies, 246

- Radiotherapy
 gonadal system disorders, 355–356
 hypothalamic-pituitary
 dysfunction, 352
- Raloxifene, 345
- Receptor activator of nuclear factor
 kappa-B ligand (RANKL), 344
- Rehabilitation issues
 cancer treatment, resuming life after
 driving, 396–397
 independent living, 396
 return to work
 and disability, 397–398
 deconditioning, 389–390
 fatigue, 389–390
 lymphedema
 breast cancer, 394
 complications, 394–395
 diagnosis, 395
 exercise, 395
 manual lymph drainage, 395
 stages, 394
 neurogenic bladder, 391–392
 neurogenic bowel, 390–391
 pain
 musculoskeletal pain, 387–388
 neuropathic pain, 388–389
 palliative rehabilitation, 386
 physiatry, 386
 preventive rehabilitation, 386
 restorative rehabilitation, 386
 spasticity
 injectable medications, 393
 intrathecal baclofen
 pump, 393–394
 Modified Ashworth Scale, 393
 oral medications, 393
 treatment modalities, 393
 supportive rehabilitation, 386
- Renal cell carcinoma (RCC), 115
 incidence, 97
 monitoring and management, 99
 surveillance and care
 eligibility, 97–99
- Restorative rehabilitation, 386
- Rickets, 348
- Rodney, A.J., 110
- Rodriguez, M.A., 1–3, 7–24, 201–214,
 287–297, 299–308, 325–341,
 343–356, 361–372, 375–383,
 385–398, 401–411, 415–419,
 421–430, 433–447
- Rose, S.R., 352
- S**
- Schmitz, K.H., 278
- Second primary cancer (SPC)
 carcinogenic pathways
 chemotherapy, 305–306
 genetic predisposition, 303–304
 ionizing radiation, 305
 lifestyle, behavioral/environmental
 factors, 304
 treatment-related effects, 304–306
 definition, 300
 field cancerization process, 300
 incidence patterns, 302–303
 prevention strategy
 lifestyle and behavioral
 changes, 307
 optimal screening, 307
 therapy-related, 306–307
 SEER program, 300
 separate/independent organ
 systems, 301
- Sexual dysfunction
 breast cancer, 404–405
 central nervous system malignancies, 404
 female
 radical pelvic surgery, 408
 rehabilitation, 410–411
 hematopoietic cancer
 chemotherapy drugs, 404
 graft-versus-host disease, 405
 hormonal replacement, 404
 testosterone replacement, 405
 male
 prostatectomy
 and cystectomy, 407–408
 radical pelvic surgery, 407
 rehabilitation, 409–410
 pelvic radiation therapy, 406–407
 physiologic changes, 402
 risk factors, 403
 types, 403
- Sexuality, 182–183
- Shimko, M.S., 100
- Silagy, C., 262, 264
- Simar, K., 201–214
- Sorafenib, 196
- SPC. *See* Second primary cancer (SPC)
- Speck, R.M., 277
- Spiess, P.E., 106
- Statins, 206
- Stem cell transplantation
 chemotherapy, 203
 immunodeficiency, 207

- immunotherapy, 203
 - myelodysplasia, 207
 - pulmonary adverse effects, 206
 - treatment options, 203–204
 - Stemmer's sign, 395
 - Steroids, 371
 - Stimulants
 - armodafinil, 370–371
 - dextroamphetamine, 370
 - methylphenidate, 369–370
 - modafinil, 370
 - Stolar, K., 167–184
 - Streptozocin, 349
 - Studer, U.E., 99, 101
 - Sun, C.C., 125–138
 - Supportive rehabilitation, 386
 - Surveillance, Epidemiology, and End Results (SEER) program, 300
 - Survivorship care
 - acute phase, 11
 - cancer patient, 9–10
 - cancer risks, both men and women, 8, 9
 - employment discrimination, 12
 - health care components, 14–15
 - intermediate phase, 11
 - long-term phase, 12
 - multidisciplinary care centers
 - oncologic specialties, 16
 - risk of recurrence, 17
 - supportive care disciplines, 16
 - tiers of care, 17
 - treatment planning, 16
 - Office of Cancer Survivorship, 10
 - overall survival rates, 9
 - Passport Plan for Health
 - document, 20–22
 - research, 23–24
 - team development, 18–20
 - therapeutic approaches, 12
 - 3-tiered model, risk stratification, 13–14
 - value-based health care delivery, 22
 - Syndrome of inappropriate antidiuretic hormone secretion (SIADH), 354
- T**
- Tamoxifen, 345
 - Testicular cancer, 120–124
 - hypogonadism, 108
 - infertility, 108–109
 - marrow failure/secondary malignancies, 110
 - metabolic syndrome and cardiovascular disease, 109
 - neurotoxicity, 109
 - renal insufficiency, 109
 - surveillance and care eligibility, 107–108
 - Thuret, R., 106
 - Thyroid cancer
 - APC gene mutation, 248
 - incidence, 242
 - PTEN gene mutation, 248
 - radioactive iodine therapy
 - gonadal effects, 245–246
 - oral and ocular
 - complication, 244–245
 - secondary malignancies, 246
 - risk factors, 248
 - surgical complications
 - hypoparathyroidism, 243
 - mobility, limitation, 244
 - vocal cord dysfunction, 244
 - thyroid-stimulating hormone suppressive therapy
 - atrial premature beats, 247
 - bone density reduction, 248
 - echocardiographic evidence, 247
 - long-term outcomes, 247
 - population-based study, 247–248
 - treatment, 246–247
 - ventricular premature beats, 247
 - Thyroid neoplasia and dysfunction
 - hyperthyroidism, 351
 - hypothyroidism, 351–352
 - ionizing radiation, 350
 - Thyroid-stimulating hormone (TSH)
 - atrial premature beats, 247
 - bone density reduction, 248
 - echocardiographic evidence, 247
 - long-term outcomes, 247
 - population-based study, 247–248
 - treatment, 246–247
 - ventricular premature beats, 247
 - T-4 lymphocytes, 376
 - Tobacco/smoking cessation program
 - hard-core smokers, 269–270
 - lung cancer, 258–259
 - mental disorders, 261
 - nicotine dependence (*see* Nicotine dependence)
 - smoking rates, 258–259
 - Tobacco Treatment Program, 270–272

Tyrosine kinase inhibitor (TKI)
cardiovascular system, 191
endocrine system, 196
immune function, 197
neurologic changes, 195–196
quality of life, 194–195
reproductive changes, 194
secondary malignancies, 192

U

Ultrasound, 59
Upper aerodigestive tract (UADT), 146
Ureteral obstruction, 380
Urothelial cancer
monitoring and management, 100–101
surveillance and care eligibility, 99–100
upper tract, 101–102

V

Vaginal atrophy, 404
Vaginal dryness, 404
Vaginal stenosis, 406
Vaginal/vulvar cancers

second primary cancer, 130
surveillance, 127, 141

Varenicline

adverse effects, 267–268
antagonistic properties, 266–267
Cochrane review, 268
double-blind clinical trial, 267

Vocal cord dysfunction, 244

W

Weight management, 289–290, 296
American Cancer Society, 280
behavioral changes
environmental changes, 283
goal setting, 282
self-monitoring, 282–283
social support, 283
portion sizes, 281
Westin, S.N., 125–138

Z

Zandstra, F., 7–24